FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328594556> ?p ?o ?g. }

• W2328594556 endingPage "42" @default.
• W2328594556 startingPage "33" @default.
• W2328594556 abstract "Background: Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1–infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ECHO) or TDF/FTC, zidovudine/lamivudine, or abacavir/lamivudine (THRIVE). The primary endpoint was confirmed response [viral load <50 copies per milliliter; intent-to-treat time-to-loss-of-virologic-response (ITT-TLOVR) algorithm] at week 48. The pooled data set enabled analyses of subgroups and predictors of response/virologic failure. Results: Confirmed responses were 84% (rilpivirine) and 82% (efavirenz). The difference in response rates (95% confidence interval) was 2.0% (–2.0% to 6.0%). The incidence of virologic failure was 9% (rilpivirine) versus 5% (efavirenz). Responses in ITT-TLOVR and ITT-snapshot analyses were consistent. Responses were similar for rilpivirine and efavirenz by background regimen, gender, race and clade. Suboptimal adherence and higher baseline viral load resulted in lower responses, higher virologic failure, and development of resistance in both groups; the effects on virologic failure were more apparent with rilpivirine. CD4+ cell count increased over time in both groups. Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs. 8%, respectively), treatment-related grade 2–4 adverse events (16% vs. 31%), rash (3% vs. 14%), dizziness (8% vs. 26%), abnormal dreams/nightmares (8% vs. 13%), and grade 2−4 lipid abnormalities. Conclusions: At week 48, rilpivirine 25 mg once daily and efavirenz 600 mg once daily had comparable response rates. Rilpivirine had more virologic failures and improved tolerability versus efavirenz." @default.
• W2328594556 created "2016-06-24" @default.
• W2328594556 creator A5004474608 @default.
• W2328594556 creator A5008173217 @default.
• W2328594556 creator A5011202454 @default.
• W2328594556 creator A5020953780 @default.
• W2328594556 creator A5024931884 @default.
• W2328594556 creator A5028130303 @default.
• W2328594556 creator A5032649947 @default.
• W2328594556 creator A5032814621 @default.
• W2328594556 creator A5032856478 @default.
• W2328594556 creator A5037765362 @default.
• W2328594556 creator A5046238828 @default.
• W2328594556 creator A5053747500 @default.
• W2328594556 creator A5061097917 @default.
• W2328594556 creator A5066136225 @default.
• W2328594556 creator A5081619260 @default.
• W2328594556 creator A5088973852 @default.
• W2328594556 date "2012-05-01" @default.
• W2328594556 modified "2023-10-05" @default.
• W2328594556 title "Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients" @default.
• W2328594556 cites W1964020548 @default.
• W2328594556 cites W1964622370 @default.
• W2328594556 cites W1973489201 @default.
• W2328594556 cites W2016257631 @default.
• W2328594556 cites W2042403739 @default.
• W2328594556 cites W2049969210 @default.
• W2328594556 cites W2052332986 @default.
• W2328594556 cites W2058643347 @default.
• W2328594556 cites W2061857819 @default.
• W2328594556 cites W2073569077 @default.
• W2328594556 cites W2083477796 @default.
• W2328594556 cites W2084302660 @default.
• W2328594556 cites W2085088518 @default.
• W2328594556 cites W2094521579 @default.
• W2328594556 cites W2099826019 @default.
• W2328594556 cites W2120602370 @default.
• W2328594556 cites W2131969088 @default.
• W2328594556 cites W2142538462 @default.
• W2328594556 cites W2161993838 @default.
• W2328594556 cites W2173615181 @default.
• W2328594556 doi "https://doi.org/10.1097/qai.0b013e31824d006e" @default.
• W2328594556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22343174" @default.
• W2328594556 hasPublicationYear "2012" @default.
• W2328594556 type Work @default.
• W2328594556 sameAs 2328594556 @default.
• W2328594556 citedByCount "147" @default.
• W2328594556 countsByYear W23285945562012 @default.
• W2328594556 countsByYear W23285945562013 @default.
• W2328594556 countsByYear W23285945562014 @default.
• W2328594556 countsByYear W23285945562015 @default.
• W2328594556 countsByYear W23285945562016 @default.
• W2328594556 countsByYear W23285945562017 @default.
• W2328594556 countsByYear W23285945562018 @default.
• W2328594556 countsByYear W23285945562019 @default.
• W2328594556 countsByYear W23285945562020 @default.
• W2328594556 countsByYear W23285945562021 @default.
• W2328594556 countsByYear W23285945562022 @default.
• W2328594556 crossrefType "journal-article" @default.
• W2328594556 hasAuthorship W2328594556A5004474608 @default.
• W2328594556 hasAuthorship W2328594556A5008173217 @default.
• W2328594556 hasAuthorship W2328594556A5011202454 @default.
• W2328594556 hasAuthorship W2328594556A5020953780 @default.
• W2328594556 hasAuthorship W2328594556A5024931884 @default.
• W2328594556 hasAuthorship W2328594556A5028130303 @default.
• W2328594556 hasAuthorship W2328594556A5032649947 @default.
• W2328594556 hasAuthorship W2328594556A5032814621 @default.
• W2328594556 hasAuthorship W2328594556A5032856478 @default.
• W2328594556 hasAuthorship W2328594556A5037765362 @default.
• W2328594556 hasAuthorship W2328594556A5046238828 @default.
• W2328594556 hasAuthorship W2328594556A5053747500 @default.
• W2328594556 hasAuthorship W2328594556A5061097917 @default.
• W2328594556 hasAuthorship W2328594556A5066136225 @default.
• W2328594556 hasAuthorship W2328594556A5081619260 @default.
• W2328594556 hasAuthorship W2328594556A5088973852 @default.
• W2328594556 hasBestOaLocation W23285945561 @default.
• W2328594556 hasConcept C126322002 @default.
• W2328594556 hasConcept C142462285 @default.
• W2328594556 hasConcept C159047783 @default.
• W2328594556 hasConcept C197934379 @default.
• W2328594556 hasConcept C2522874641 @default.
• W2328594556 hasConcept C2777869810 @default.
• W2328594556 hasConcept C2778715236 @default.
• W2328594556 hasConcept C2778723075 @default.
• W2328594556 hasConcept C2779465607 @default.
• W2328594556 hasConcept C2779778239 @default.
• W2328594556 hasConcept C2780216070 @default.
• W2328594556 hasConcept C2780593183 @default.
• W2328594556 hasConcept C2780727368 @default.
• W2328594556 hasConcept C2781432083 @default.
• W2328594556 hasConcept C2993143319 @default.
• W2328594556 hasConcept C3013748606 @default.
• W2328594556 hasConcept C71924100 @default.
• W2328594556 hasConceptScore W2328594556C126322002 @default.
• W2328594556 hasConceptScore W2328594556C142462285 @default.
• W2328594556 hasConceptScore W2328594556C159047783 @default.
• W2328594556 hasConceptScore W2328594556C197934379 @default.
• W2328594556 hasConceptScore W2328594556C2522874641 @default.

• next